CD274 and neoplasm: Most studies published on PD-L1 expression are performed in the primary tumour and are based on immunohistochemistry, and have shown a significant variation in results, limiting the use of PD-L1 expression by immunohistochemistry as a prognostic biomarker in clinical practice27.